<DOC>
	<DOCNO>NCT00600782</DOCNO>
	<brief_summary>This study ass safety immunogenicity GSK Biologicals ' candidate TB vaccine administer 0 , 1 month healthy adult live TB-endemic region . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Immunogenicity Safety Candidate Tuberculosis ( TB ) Vaccine Given Healthy Adults TB-endemic Region</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects Investigator believe comply requirement protocol . A male female , include , 21 40 year age time first vaccination . Written inform consent obtain subject prior study procedure . Free obvious health problem establish medical history clinical examination enrolment study . If subject female , must nonchildbearing potential , childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month completion vaccination series . No evidence pulmonary pathology confirm chest Xray . Clinically normal laboratory value creatinine , ALT , AST complete blood count . Seronegative human immunodeficiency virus1 ( HIV1 ) . No history extrapulmonary TB . Subjects must appropriate PPD skin reactivity ( induration measure 48 72 hour PPD skin test administration ) . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within 6 month prior first vaccine dose . History previous administration experimental Mycobacterium tuberculosis vaccine . History previous exposure experimental product contain MPL QS21 . Administration immunoglobulins , immunotherapy and/or blood product within three month precede first dose study vaccination , plan administration study period . Participation another experimental protocol study period . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination . A family history congenital hereditary immunodeficiency . Subjects describe firstdegree relative clearly document autoimmune disease exclude History acute chronic illness medication , opinion Investigator , may interfere evaluation safety immunogenicity vaccine . Any chronic drug therapy continue study period , exception vitamin and/or dietary supplement , birth control pill , antihistamine seasonal allergy , SSRIs . History neurologic disorder seizure . History allergic reaction anaphylaxis previous immunisation . History allergic disease reaction likely exacerbate component vaccine . History chronic alcohol consumption and/or drug abuse investigator opinion would put subject risk . Major congenital defect . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Tuberculosis vaccine</keyword>
</DOC>